The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1442
ISSUE 1442
May 12, 2014
Issue 1442
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction
May 12, 2014 (Issue: 1442)
The FDA has approved avanafil (Stendra – Vivus),
an oral phosphodiesterase type-5 (PDE5) inhibitor,
for treatment of erectile dysfunction. It is the fifth
PDE5 inhibitor to be approved for this indication.
Advertisements on Stendra’s website...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.